GET DAILY SIGNALSEarnings Season Provides Renewed Optimism for Traders
Ongoing trade disputes, political divisiveness, geopolitical threats, and tense feelings about Russia meddling have no doubt weighed on investor sentiment. Though the S&P 500 is up year-to-date, volatility has been pervasive and global stocks are still in negative territory. Uncertainty hangs over the market like a dark cloud.
But there's sun poking through those dark clouds, and it's none other than U.S. corporate earnings reports! Indeed, earnings have offered a bright spot amidst the negativity, and now in their second week, earnings have been impressing the street and renewing optimism amongst investors for stocks.
Here are a few highlights from this week:
Shares of Eli Lilly were climbing Tuesday on the pharmaceutical company's announcement that it earned $1.55 billion, or $1.50 per share, which was far ahead of analysts estimates of $1.30 per share. Eli Lilly also announced that it would file an IPO for its animal health unit, which the street cheered. Last quarter, Eli Lilly's net income was $1.01 billion, or 95 cents per share. On the revenue front, Eli Lilly hit $6.36 billion, up 9% from the year-ago quarter and above estimates of $6.05 billion. Lilly has approved a plan to buy back $8 billion in stock.
In the telecommunications sector, Verizon shares were also notching higher on reported earnings of $1.20 a share, above a consensus estimate of $1.14. This is good news for the telecom sector, which has taken a beating so far this year, down some 12% year to date while the S&P 500 is in modestly positive territory. AT&T will be one to watch this week as well, to see if telecom can keep getting a much needed boost.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LLY in upward trend: 10-day moving average moved above 50-day moving average on October 15, 2026
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 51 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for LLY just turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 233 of 297 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (37.296) is slightly higher than the industry average of (-1.376). P/E Ratio (47.489) is within average values for comparable stocks, (21.842). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.039) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement